Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug runimotamab takes on Hard-to-Treat HER2 cancers

NCT ID NCT03448042

Ongoing Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called runimotamab, alone or with trastuzumab, in 123 people with advanced HER2-positive cancers. The main goal is to check safety and how the drug moves through the body. It is for patients whose cancer has spread or cannot be removed by surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
runimotamab (with trastuzumab and tocilizumab as needed)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced HER2-positive cancers that are hard to treat.
What could go wrong
This is an early phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may not work or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-EXPRESSING BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer gastroesophageal junction adenocarcinoma HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

  • ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda

    Milan, Lombardy, 20162, Italy

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Centre Léon Bérard

    Lyon, Rhône, 69008, France

  • China Medical University Hospital

    Taichung, 40447, Taiwan

  • Churchill Hospital

    Oxford, Oxfordshire, OX3 7LJ, United Kingdom

  • EDOG - Institut Bergonie - PPDS

    Bordeaux, Gironde, 33000, France

  • Grand Hopital de Charleroi asbl

    Charleroi, 6000, Belgium

  • Gustave Roussy

    Villejuif, Val-de-Marne, 94805, France

  • Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis

    Amsterdam, 1066 CX, Netherlands

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario Quironsalud Madrid

    Pozuelo de Alarcón, Madrid, 28223, Spain

  • Institut Claudius Regaud

    Toulouse, 31059, France

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10017, United States

  • National Cancer Center East

    Chiba, 277-8577, Japan

  • National Cancer Centre

    Singapore, 168583, Singapore

  • National Taiwan University Hospital

    Taipei, 10048, Taiwan

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • Princess Margaret Hospital

    Toronto, Ontario, M5G 2M9, Canada

  • Rigshospitalet-Blegdamsvej 9

    Copenhagen, 2100, Denmark

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • START MADRID_Hospital Universiario Fundacion Jimenez Diaz

    Madrid, 28040, Spain

  • START MADRID_Hospital Universitario HM Sanchinarro - CIOCC - EDOS

    Madrid, 28050, Spain

  • Seoul National University Hospital

    Seoul, 110-744, South Korea

  • Washington University

    Saint Louis, Michigan, 63130, United States

  • Yale University

    New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.